Build Your Own Case Study | From Evidence to Practice: Enhancing T2D Outcomes with Informed Approaches on Obesity

Estimated Time
1.0 hour

Release Date
Jan 15, 2024

Expiration Date
Jan 14, 2025

The tie between type 2 diabetes (T2D) and overweight/obesity is a significant global public health issue, supported by decades of extensive research. Despite formal clinical guidelines recommendations in addressing both diseases, the initiation or intensification of therapies that improve glycemic control and achieve weight reduction targets are slowly adopted into clinical practice, particularly for patients with T2D. Given the overlap of these two conditions, it is imperative that healthcare providers worldwide align clinical practice with evidence-based guidelines and the latest clinical findings using newer agents to treat both diseases.

In this immersive virtual Build Your Own Case Study  | From Evidence to Practice: Enhancing T2D Outcomes with Informed Approaches on Obesity, navigate through your toughest clinical challenges across the globe while leading experts reinforce essential topics, such as:

  • Evidence-based approaches in the treatment and management of T2D
  • Integrating weight loss as a therapeutic intervention your patients with T2D
  • Best practices in shared decision-making and patient communication to create individualized treatment plans


Accreditation and Disclosure Information

Target Audience
This activity is intended for endocrinologists, diabetologists, primary care physicians, and other HCPs who are involved in the care of patients with T2D.

Educational Objectives
After completing this activity, the participant should be better able to:

  • Utilize evidence-based approaches in the treatment and management of T2D to mitigate clinical inertia, including routine screening, follow-up monitoring, treatment intensification, and the incorporation of new therapeutic options to achieve optimal glycemic control
  • Select appropriate treatment for T2D that integrates weight loss as an early therapeutic intervention in accordance with ADA-EASD consensus guidelines, including the use of single and dual GIP/GLP-1 agonists
  • Employ shared decision-making strategies to develop individualized treatment plans for patients with T2D, including weight loss, with consideration of patient preferences and goals, in order to enhance treatment adherence and improve patient satisfaction
  • Develop effective communication skills and strategies to discuss weight loss as a goal for patients with T2D

Program Agenda

  • Discuss recent recommendations from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) on approaches to glycemic and weight management.
    • Global health burden of T2D and overweight/obesity
    • Discuss the impact of clinical inertia in the management of T2D, including weight management strategies
    • Examine evidence-based screening metrics for glycemic and weight monitoring and management
    • Analyze patient clinical presentation, medical history, and relevant labs (such as comorbidities, HbA1C, BMI, waist circumference) to support timely and accurate diagnosis and create individualized treatment regimens 
    • Analyze clinical case scenarios for timely and appropriate treatment intensification
    • Review the holistic-centered approach to managing T2D, encompassing glycemic control, weight management, cardiovascular risk, and cardiorenal protection benefits provided by novel therapies.
  • Discuss the application and suitable patients for approved and emerging treatment options in T2D management, including patients with overweight/obesity conditions.
    • Select appropriate therapies and/or a combination of antidiabetic and anti-obesity medications that address hyperglycemia and weight management in newly diagnosed patients with T2D, patients in need of treatment intensification, and patients with T2D and overweight/obesity conditions
    • Manage and mitigate side effects of GLP-1 RAs and dual GIP/GLP-1 RA therapies to promote adherence and patient satisfaction
  • Adopting patient-centered approaches in shared decision-making and effective communication
    • Language Matters: Modeling effective communication in the discussion of weight management for patients with T2D
    • Incorporate shared decision-making strategies for optimal therapy selection based on patient-specific factors and preferences
    • Consider social determinants of care (e.g., access, socioeconomic status, disease complications).

Accreditation, Support and Credit



Joint Accreditation with Commendation Logo
In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

EBAC Credit

Medical Learning Institute, Inc. is an EBAC® accredited provider effective October 2023.

This programme is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1.0 hour of external CE credit. Each participant should claim only those hours of credit that have actually been spent in the educational activity.

ECMEC® Credit

ECMEC LogoThe European Union of Medical Specialists-European Accreditation Council for Continuing Medical Education (UEMS-EACCME®) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit(s)™ into European CME credit (ECMEC®) should contact the UEMS (

Physician Associate Credit Designation Statement
Medical Learning Institute, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until January 14, 2025. PAs should only claim credit commensurate with the extent of their participation.

Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour and 1.0 contact hour in the area of pharmacology.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Support Statement
This activity is supported by an educational grant from Lilly.

Disclosure & Conflict of Interest Policy
Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.

In compliance with EBAC guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CE activities.

Faculty Disclosures
Course Director/Planner/Presenter

Stefano Del Prato, MD
Affiliate Professor
Interdisciplinary Research Center “Health Science”
San’Anna School of Advanced Studies
Pisa, Italy

Stefano Del Prato, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: Abbott, Amarin Corporation, Applied Therapeutics, Eli Lilly, EvaPharma, Hengrui Therapeutics Inc, Menarini International, Novo Nordisk, Sandoz, Sun Pharmaceuticals
Speakers’ Bureau: AstraZeneca, Boehringer Ingelheim, Berlin-Chemie, Eli Lilly, Laboratori Guidotti, Merck & Co., Novo Nordisk, Sanofi
The following relationships have ended within the last 24 months:
Research Grant: AstraZeneca, Boehringer Ingelheim

Luca Busetto, MD

Associate Professor of Internal Medicine at the Department of Medicine
University of Padova
Center for the Study and the Integrated Treatment of Obesity
Padova University Hospital
Padua, Italy

Luca Busetto, MD, has a financial interest/relationship or affiliation in the form of:
The following relationships have ended within the last 24 months:
Advisory Board/Consultant: Eli Lilly, Novo Nordisk, Pfizer
Speakers’ Bureau: Rhythm Pharmaceuticals

Stephan Jacob, MD

Internist, Endocrinologist, Diabetologist, Nutrition Specialist, Clinical Hypertension Specialist
University of Tübingen and Cardio Metabolic Institute
Praxis für Prävention und Therapie
Villingen-Schwenningen, Germany

Stephan Jacob, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: Boehringer Ingelheim, Lilly, Novo Nordisk
Speakers’ Bureau: AstraZeneca, Boehringer Ingelheim, Lilly, Novo Nordisk

Tina Vilsbøll, MD, DMSc

Steno Diabetes Center Copenhagen
University of Copenhagen
Copenhagen, Denmark

Tina Vilsbøll, MD, DMSc, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: AstraZeneca, Boehringer, GlaxoSmithKline, Lilly, Mundipharma, Novo, Sanofi, Syn Pharmaceuticals
Research Grant: Lilly, Novo
Speakers’ Bureau: AstraZeneca, Boehringer, GlaxoSmithKline, Lilly, Mundipharma, Novo, Sanofi, Syn Pharmaceuticals

All of the relevant financial relationships of individuals for this activity have been mitigated.

Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, do not have any relevant financial relationships to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. You will receive your certificate from Medical Learning Institute, Inc. If you have questions regarding your certificate, please contact

For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.

For Physicians requesting MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit.

About This Activity
Medical Learning Institute, Inc. is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by an educational grant subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.

Copyright © 2024 Medical Learning Institute, Inc. All Rights Reserved.